FOURTH WAIVER AGREEMENT TO CREDIT AGREEMENTFourth Waiver Agreement • March 22nd, 2017 • Kadmon Holdings, Inc. • Pharmaceutical preparations • New York
This FOURTH WAIVER AGREEMENT TO CREDIT AGREEMENT, dated as of March 22, 2017 (this “Agreement”), is entered into by and among Kadmon Pharmaceuticals, LLC, a Pennsylvania limited liability company (the “Borrower”), the guarantors party hereto and each of the lenders listed on the signature pages hereof under the heading “LENDERS”. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement (defined below).
SECOND AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 22nd, 2017 • Kadmon Holdings, Inc. • Pharmaceutical preparations
This Second Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 and amended on May 20, 2016 (collectively, the “Agreement”). Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.
THIRD AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • March 22nd, 2017 • Kadmon Holdings, Inc. • Pharmaceutical preparations
This Third Amendment modifies the Supply and Distribution Agreement by and between Kadmon Pharmaceuticals, LLC, a Pennsylvania Limited Liability Company (“KADMON”), with its principal place of business at 119 Commonwealth Drive, Warrendale, PA 15086 and Camber Pharmaceuticals, Inc., a Delaware company (“CAMBER”), with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854, effective as of February 23, 2016 and amended on May 20, 2016 and August 23, 2016 (collectively, the “Agreement”). Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Agreement.
